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Oncogenic KRAS regulates asparagine
synthaseDana Gwinn, Eric Alejandro Sweet-Cordero
Stanford University, Stanford, CAKras is a small GTPase that functions in the trans-
mission of extracellular mitogenic stimuli, and is one of
the most frequently mutated genes in non-small cell
lung cancer (NSCLC). Previously, Kras has been
demonstrated to play a role in tumor metabolism in
certain cell types and cancers, but this has yet to be
analyzed in the context of NSCLC. We have analyzed
how Kras changes metabolic gene expression by
expressing a doxycycline-inducible hairpin against
Kras in several NSCLC cell lines. One of the most
regulated metabolism genes is asparagine synthetase
(Asns), which transfers the g-amino group of glutamine
to aspartate, yielding glutamate and asparagine. We
ﬁnd elevated levels of Asns in Kras mutant tumors, and
that expression of Asns correlates with poor patient
outcome. Knockdown of Asns in the absence of exog-
enous asparagine in the media results in inhibition of
cell growth and induction of apoptosis that is rescued
by addition of asparagine. Additionally, under condi-
tions of low glutamine levels, knockdown of Asns
sensitizes cells to apoptosis, and overexpression of
Asns is protective under these conditions. We also ﬁnd
a role for the glutaminase-activity of Asns in glutamine-
mediated anapleurosis of the TCA cycle. These obser-
vations suggest Asns may be an interesting and novel
therapeutic target for NSCLC tumors with mutations in
Kras.
Blood-based biomarkers for lung
cancer: Ready for prime time?Anil Vachani University of Pennsylvania,
Philadelphia, PABlood based biomarkers have the potential for
improving outcomes in lung cancer, a disease where
approximately 40% of patients present with distant
metastases at diagnosis. Two important areas of
research include the discovery of risk biomarkers (e.g.
deﬁning who will develop lung cancer in the future) and
the identiﬁcation of diagnostic biomarkers for use as a
screening tool or to assess the likelihood of cancer in
patients with a radiographic abnormality such as a lung
nodule. Although the pace of biomarker discovery isadvancing rapidly across all of these areas, the devel-
opment of biomarkers to assess the likelihood of cancer
in patients with lung nodules has been an intense area of
research and several biomarkers are currently being
evaluated in prospective trials.
Lung nodules are increasingly identiﬁed either inci-
dentally or through the use of screening low dose chest
CT. Lung nodules deemed indeterminate lack the fea-
tures suggestive of benign etiologies and present clini-
cians with a diagnostic conundrum. Although most lung
nodules are benign, patients frequently undergo multiple
diagnostic tests, including the use of positron emission
tomography (PET), as well as invasive procedures such
as transthoracic needle aspiration, bronchoscopy and/or
surgery. Therefore, biomarker strategies to distinguish
between malignant and benign lung nodules may miti-
gate the diagnostic burden faced in this setting.
Peripheral blood based detection strategies are an
attractive approach for diagnostic markers, given the
ease of acquisition and potential for serial testing, and
are based on the underlying hypothesis that molecular
alterations of tumor cells lead to the synthesis of distinct
molecular species that can be detected in the blood.
Peripheral blood biomarkers have been identiﬁed in
both the cellular component (circulating tumor cells,
white blood cells) and in the non-cellular fraction (e.g.
plasma, serum), and studies have spanned across several
different types of molecular species.
The presentation will review the rationale for the use
of early detection biomarkers for risk assessment,
screening, and diagnosis, and provide a comprehensive
overview of blood based biomarkers currently in
development, including markers that are available for
clinical use. This will include an analysis of existing data
from clinical validation and utility studies supporting the
use of blood based diagnostic tests as well as a discus-
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The CRISPR/Cas9 bacterial system uses short non-cod-
ing RNAs as an adaptive defense mechanism against
invading DNAs. This system has recently been adapted
as a tool to edit mammalian genomes, and requires only
the co-expression of the Cas9 endonuclease and a short
guide RNA that can direct it to target loci.
February 2016 Abstracts S15I will discuss novel applications of the CRISPR/Cas9
for in vivo somatic editing. More speciﬁcally, I will pre-
sent data showing that in vivo delivery of pairs of guide
RNAs can be used to generate cancer-promoting chro-
mosomal rearrangements, enabling us to rapidly
generate more faithful mouse models of human cancers.
Lastly, I will discuss how we are applying this novel
technology for functional genomic screens aimed at
identifying cancer associated non-coding RNAs and DNA
regulatory elements.Intratumoral heterogeneity and
EGFR-TKIs resistanceCaicun Zhou, Weijing Cai Shanghai Pulmonary
Hospital; Tongji University Medical School
Pulmonary Cancer Institute, Shanghai, China
Lung cancer is one of the malignant tumors with the
highest degree of heterogeneity. Intratumoral hetero-
geneity includes histopathologic heterogeneity and ge-
netic heterogeneity. Intratumoral heterogeneity,
especially genetic heterogeneity, plays an important
role in resistance to targeted therapy. Some previous
studies have proved that Intratumoral heterogeneity is
one of the mechanism of EGFR-TKIs resistance in lung
cancer. The patients with NSCLC harboring T790Mmutation before targeted therapy had a poor response
to EGFR-TKIs. Besides, increasingly more lung cancers
were identiﬁed to harbor EGFR mutations and ALK
fusions concurrently with the development of gene
detection technology. Current studies on the explora-
tion of intratumoral heterogeneity did not go far
enough. Firstly, not all T790M or C797S mutations
which were identiﬁed in tumor cells after acquired
resistance were present due to treatment selection.
Secondly, the mechanism and treatment strategy for
lung cancer with dual altered driver remain contro-
versial. Finally, abundance of EGFR mutations caused
by intratumoral heterogeneity may affect the response
to EGFR-TKIs. Our team has done a lot of work on this
aspect. Our study identiﬁed intratumoral heterogeneity
in lung adenocarcinoma with dual oncogenic drivers. In
addition, we found patients with low abundance of EGFR
mutations had poor response to EGFR-TKIs. The ORR
for patients with high abundance of EGFR mutations
(HA-EGFR) was signiﬁcantly higher compared with
patients with low abundance of EGFR mutations
(LA-EGFR) (72.9% vs. 11.7%, P<0.001). The median PFS
in HA-EGFR group was also signiﬁcantly longer than
that in LA-EGFR group (19del subgroup: 15.0 vs 4.0
months, P<0.001; L858R subgroup: 12.0 vs 2.0,
P<0.001). In conclusion, intratumoral heterogeneity may
be an important reason for EGFR-TKIs resistance in lung
cancer.
